Kaplan Meier News Today

Neoadjuvant nivolumab with chemotherapy led to durable EFS benefit and a trend toward improved OS vs chemotherapy alone in patients with resectable NSCLC.

CHICAGO — Glucagon-like peptide-1 receptor agonists lowered the risk for obesity-related cancers compared with bariatric surgery among individuals with a BMI of at least 35, according to data presented at ASCO Annual Meeting. Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) conferred a greater risk reduction in all-cause mortality, despite inferior weight loss results

Zanidatamab has received priority review from the FDA for the treatment of patients with HER2-positive metastatic biliary tract cancer.

Zanidatamab is a HER2-targeted bispecific antibody that can simultaneously bind 2 non-overlapping epitopes of the HER2 receptor.

04.05.2024 - UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from a new analysis of the ATLAS trial, which estimates using ... Seite 1

New and Recurrent Patients Treated with UGN-102 Achieved Similar Durability of Response Rates at 12 months ...

Treatment with 177Lu-PNT2002 resulted in a significant improvement in radiographic progression-free survival vs abiraterone acetate or enzalutamide in patients with metastatic castration-resistant prostate cancer whose disease had progressed on an androgen receptor pathway inhibitor.

The FDA has issued a complete response letter to the biologic license application seeking the approval of cosibelimab for use in patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not eligible for curative surgery or radiation.

WILMINGTON, Del. & WALTHAM, Mass.--(BUSINESS WIRE)--Dec 10, 2023--

- Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg dose achieving a complete or partial response within the first six months of treatment - Data are...